Guardant Health GH 深 沪
已收盘 08-21 16:00:00 美东时间
170.69
+2.810
+1.67%
华盛通- 最 高170.85
- 今 开167.25
- 成交量 191.68万股
- 最 低 165.01
- 昨 收 167.88
- 总市值 2290.59万
- 52周最高 176.58
- 市盈率 静 --
- 换手率 1.43%
- 52周最低 53.40
- 委 比 -40.19%
- 总股本 0.00亿
- 历史最高 181.07
- 量 比 0.71
- 振 幅 3.48%
- 历史最低 15.81
- 每 手 1
- 风险率 30.46%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Insight Molecular Diagnostics to Host Virtual KOL Event on August 17, 2026: Moving Toward In-House Heart Transplanted Organ Rejection Testing
Insight Molecular Diagnostics Inc. (iMDx) will host a virtual KOL event on August 17, 2026, featuring Max Jacob Liebo, MD, Nick Ioannou, MD, MHA, and Josh Riggs to discuss the GraftAssure platform, which uses digital PCR technology for reliable dd-cfDNA results in transplant organ monitoring. The event will cover the FDA-reviewed GraftAssureDx test for kidney transplant rejection and its implications for heart transplants. iMDx aims to bring test...
08-11 20:05
美股大行评级 | Palantir、Snap、爵士制药获多家大行上调目标价；潜在涨幅176.34%！巴克莱维持Snap(SNAP)"超配"评级，目标价从15美元上调至16美元
今日重点评级关注：巴克莱：维持Snap"超配"评级，目标价从15美元升至16美元；Canaccord Genuity：维持阿梅雷斯克"买入"评级，目标价从59美元升至62美元
08-05 11:45
美股大行评级 | 潜在涨幅3586.64%！HC Wainwright上调Enlivex目标价至80美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Enlivex"买入"评级，目标价从20美元升至80美元；Canaccord Genuity：维持Pharming Group NV Sponsored ADR"买入"评级，目标价从37美元升至38美元
08-04 11:45
美股大行评级 | 最高400美元！亚马逊绩后获11家大行上调目标价；苹果绩后评级分歧大！3家上调，3家下调；德康医疗、万事达、神经分泌生物科学获多家大行上调目标价
今日重点评级关注：TD Cowen：维持加拿大鹅"买入"评级，目标价从13美元升至18美元；瑞银：维持吉登运动服"买入"评级，目标价从110美元升至111美元
08-03 11:38
财报速睇 | Guardant Health 2026财年Q2营收3.35亿美元，同比增长44.4%；归母净利润亏损1.20亿美元，同比亏损扩大20.0%
华盛资讯8月2日讯，Guardant Health公布2026财年Q2业绩，公司Q2营收3.35亿美元，同比增长44.4%，归母净利润亏损1.20亿美元，同比亏损扩大20.0%。
08-02 05:32
Guardant Health hits 52-week high after guidance hike
Guardant Health (GH) added nearly 10% at the market open on Friday to hit a new 52-week high after the blood-based cancer test maker reported Q2 2026 revenue well surpassing the consensus and raised i...
07-31 22:34
Amazon To Rally Around 55%? Here Are 10 Top Analyst Forecasts For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Barclays raised the price target for Crocs Inc (NASDAQ:CROX) from $110 to $118. Barclays analyst Adrienne Yih ...
07-31 20:15
BTIG Maintains Buy on Guardant Health, Raises Price Target to $195
BTIG analyst Mark Massaro maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $190 to $195.
07-31 18:29
Guardant Health Files Shelf Prospectus For Offering; Size Not Disclosed
Guardant Health Files Shelf Prospectus For Offering; Size Not Disclosed
07-31 05:37
Next Century Growth Investors exits Bloom Energy, Coherent; adds DigitalOcean in Q2
In its Q2 portfolio update, Next Century Growth Investors disclosed nine new positions across three sectors. The industrial additions were Park Aerospace Corp. (PKE), IPG Photonics Corporation (IPGP),...
07-24 23:00
